PGOLD Fair Value & Analysis
Consumer Non-Cyclicals · PH · Market cap 144B PHP
Fair value as of: Jul 10, 2026
From 26 valuation models · updated 30 days ago
Fair value updated Jul 10, 2026, revised from 72.73 PHP to 62.75 PHP (−13.7%) since Jun 24, 2026. Share price −14.8% over the past month.
A solid business, screening 60% undervalued on our models.
What matters now
- Solid quality (60/100) at a price below fair value, the discount is the argument here, not the business quality.
- A fairly wide model range (37.88 PHP to 78.44 PHP) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 10, 2026.
How to read this chart
60‑month range 20.29 PHP – 49.00 PHP · fair‑value band 37.88 PHP – 78.44 PHP · the 39.30 PHP price screens below the 62.75 PHP fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 10, 2026.
Analysis
PGOLD (PGOLD) currently trades at 39.30 PHP, while our model-based Fair Value estimate is 62.75 PHP, implying the stock looks roughly 59.7% undervalued today. The Quality Score stands at 60/100 (solid quality), in the Consumer Non-Cyclicals sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
The stock trades on a trailing P/E of 19.5. Fundamentals as of Jul 10, 2026
Our scenario range runs from 37.88 PHP (bear case) to 78.44 PHP (bull case); at 39.30 PHP, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 20% below its 52-week high and 24% above its 52-week low. For context, the median of 10 Consumer Non-Cyclicals peers we cover trades at -18% fair-value upside, at 60%, PGOLD screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models (61.94 PHP) versus Asset-Based (17.69 PHP). Highest evidence: Growth DCF (80).
Quality Score breakdown
Of which business quality 59 · Market factors (momentum, volatility) 50
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
Revenue & earnings trend
FY2020 – FY2024 · reported fiscal years
PGOLD reported revenue of 219B PHP in FY2024 versus 169B PHP in FY2020, a compound +6.8%/yr. Reported net income was 10.4B PHP in FY2024, compounding +6.6%/yr from FY2020.
Watch PGOLD: get an alert when its fair value changes →
Peer Group
Consumer Discretionary · 3559 stocks
How this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Food & Drug Retailing” was too small, so the broader sector is used.)
Valuation Multiples vs Consumer Discretionary median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 35/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Food & Drug Retailing stocks, each showing price versus our Fair Value estimate (as of Jul 10, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| RRHI RRHI | 38.00 PHP | 43.51 PHP | +15% |
| KEEPR KEEPR | 1.86 PHP | 6.15 PHP | +231% |
| Gimat Magazacilik Sanayi Ve Ticaret A.S. GMTAS | 46.70 TRY | 8.96 TRY | -81% |
| Curexo Inc 060280 | 8,000 KRW | 1,147 KRW | -86% |
| FRUIT FRUIT | 0.6700 PHP | 0.5500 PHP | -18% |
| Seouleaguer Co 043710 | 2,850 KRW | 811.29 KRW | -72% |
| COSCO COSCO | ₹208.00 | ₹51.24 | -75% |
| FB FB | 49.00 PHP | 49.03 PHP | +0% |
| JGS JGS | 25.00 PHP | 20.51 PHP | -18% |
| URC URC | 61.20 PHP | 47.86 PHP | -22% |
Compare PGOLD with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
Frequently asked questions
Is PGOLD overvalued or undervalued?
What is the fair value of PGOLD?
What is the quality score of PGOLD?
What is the net profit margin of PGOLD?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track PGOLD and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.